Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
27/10/2023 22:16
Oct 27 (Reuters) - Obseva SA OBSN.S :
* XOMA WILL BE RECEIVING FULL WORLDWIDE RIGHTS ON EBOPIPRANT
FOLLOWING TERMINATION OF LICENSE AGREEMENT WITH ORGANON
* CONTINGENT MILESTONE PAYMENTS WILL NO LONGER BE AVAILABLE
TO CO
Source text for Eikon: ID:nGNE3jM9W5
Further company coverage: OBSN.S
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary